Prime Medicine Inc PRME
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $3.41
- Day Range
- $3.40–3.65
- 52-Week Range
- $3.28–9.86
- Bid/Ask
- $3.45 / $3.52
- Market Cap
- $421.31 Mil
- Volume/Avg
- 1.5 Mil / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 605.80
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 234
- Website
- https://www.primemedicine.com
Comparables
Valuation
|
Metric
|
PRME
|
NTLA
|
CRSP
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.14 | 1.82 | 1.95 |
Price/Sales | 605.80 | 34.90 | 18.48 |
Price/Cash Flow | — | — | — |
Price/Earnings
PRME
NTLA
CRSP
Financial Strength
|
Metric
|
PRME
|
NTLA
|
CRSP
|
|---|---|---|---|
Quick Ratio | 7.85 | 6.69 | 0.00 |
Current Ratio | 8.23 | 7.21 | 15.73 |
Interest Coverage | — | — | — |
Quick Ratio
PRME
NTLA
CRSP
Profitability
|
Metric
|
PRME
|
NTLA
|
CRSP
|
|---|---|---|---|
Return on Assets (Normalized) | −70.16% | −28.75% | −8.47% |
Return on Equity (Normalized) | −89.48% | −34.94% | −10.08% |
Return on Invested Capital (Normalized) | −78.46% | −35.82% | −9.15% |
Return on Assets
PRME
NTLA
CRSP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lkxpdtkmy | Vqzyv | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pjzdcjvtc | Gfzkwpn | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ygmgzfqr | Xrlpj | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fkxymjtp | Tnbckz | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Xxhgxnr | Nyrjw | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Mmzcbpgn | Zhkr | $29.2 Bil | |||
| Moderna Inc
MRNA
| Rnpwbwmvt | Zdmn | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Vhhzcgc | Bjsg | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Sqzzhhrq | Twpfcd | $13.2 Bil | |||
| Incyte Corp
INCY
| Hxtvwdl | Qrlnly | $13.0 Bil |
United States